Press Releases CervoMed Inc.

Equities

CRVO

US15713L1098

Real-time Estimate Cboe BZX Other stock markets 10:41:14 2024-05-14 am EDT			5-day change	1st Jan Change
24.63 ^USD	+0.74%		-0.20%	+219.13%

Apr. 08	Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating	MT
Mar. 29	CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CervoMed : Nominating and Corporate Governance Committee Charter	May. 05	PU
CervoMed : Corporate Presentation April 2024	Apr. 21	PU
CervoMed : Corporate Presentation April 2024	Apr. 03	PU
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates	Apr. 01	AQ
CervoMed to Participate in Upcoming Investor Conferences	Mar. 28	AQ
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors	Mar. 28	AQ
CervoMed : Shareholder Meeting - Form 8-K	Mar. 18	PU
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024	Mar. 05	AQ
CervoMed to Participate in the BIO CEO and Investor Conference	Feb. 21	AQ
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board	Feb. 20	AQ
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies	Feb. 12	AQ
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board	Feb. 07	AQ
CervoMed to Participate in the Emerging Growth Conference 67	Feb. 05	AQ
CervoMed to Participate in the Emerging Growth Conference 66	Jan. 05	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies	23-10-26	AQ
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias	23-10-25	AQ
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies	23-10-19	AQ
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference	23-10-06	AQ
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW